Condition: Migraine Disorders · Sponsor: Cerenovus, Part of DePuy Synthes Products, Inc.
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
This description comes directly from the study's public registry record.
Study Contact · RA-MIGRAINECNV202302@ITS.JNJ.com
Always discuss trial participation with your own doctor first.
| Barrow Neurological Institute at St. Joseph's Hospital | Phoenix, Arizona, United States | Withdrawn |
| John Muir Physician Network Clin. Research Center | Walnut Creek, California, United States | Not Yet Recruiting |
| Hartford Hospital | Hartford, Connecticut, United States | Recruiting |
| University of Buffalo Medical Center | Buffalo, New York, United States | Not Yet Recruiting |
| Mount Sinai | New York, New York, United States | Recruiting |
| Stony Brook University Medical Center | Stony Brook, New York, United States | Recruiting |
| Thomas Jefferson University Hospital | Philadelphia, Pennsylvania, United States | Recruiting |
| Semmes Murphey Foundation | Memphis, Tennessee, United States | Recruiting |
| West Virginia University | Morgantown, West Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06735833